Vijaya Diagnostic Centre Share Price Target 2027: What Earnings Say About Rs 1,720 and Rs 2,060
- November 6, 2026
- Posted by: Chaitanya Auti
- Category: Market
Vijaya Diagnostic Centre share price Rs 1,461.20 (6 November 2026). Base target Rs 1,720, bull Rs 2,060, downside risk Rs 1,146. PE 72.44. 52W range Rs 848.00 to Rs 1,593.60.
Quick Answer
The Vijaya Diagnostic Centre share price target for 2027 is Rs 1,720, about 17.7% above the current price of Rs 1,461.20. The bull case is Rs 2,060, and the downside risk level, which is not a target, is Rs 1,146. The base case assumes earnings per share grow 20.0% a year, a cap applied because the FY24 to FY26 pace was 20.4%, with the stock holding its PE of 72.44. These are model-based estimates built from reported financials, not guaranteed outcomes.
Investors weighing a Vijaya Diagnostic Centre target price for 2027 should start with where the stock sits today. At Rs 1,461.20 on 6 November 2026, it is 8.3% below its 52-week high of Rs 1,593.60 and 72.3% above its 52-week low of Rs 848.00. That range spans 88% from low to high, so the entry point matters as much as the Vijaya Diagnostic Centre price forecast itself.
This article builds the Vijaya Diagnostic Centre share price target from reported numbers only: five years of annual results, the last five quarters, the latest shareholding pattern and current valuation ratios from company filings and exchange data. Each scenario states its assumptions, so you can trace how the base case, the bull case and the downside risk level were reached and test them against your own view.
Click Here – Get Free Investment Predictions
Vijaya Diagnostic Centre Stock Analysis: Company Overview and Key Stats
Vijaya Diagnostic Centre (NSE: VIJAYA) has a market capitalisation of Rs 14,759 crore. In FY26 it reported revenue of Rs 835 crore and net profit of Rs 172.98 crore. The table collects the figures the Vijaya Diagnostic Centre share price target is built on.
| Metric | Value |
|---|---|
| Company | Vijaya Diagnostic Centre |
| NSE Ticker | VIJAYA |
| CMP (6 November 2026) | Rs 1,461.20 |
| 52-Week High | Rs 1,593.60 |
| 52-Week Low | Rs 848.00 |
| Market Cap | Rs 14,759 crore |
| PE Ratio (TTM) | 72.44 |
| Industry PE | 63.24 |
| Price to Book | 13.96 |
| Return on Equity | 19.26% |
| Debt to Equity | 0.48 |
| EPS (TTM) | Rs 19.78 |
| Dividend Yield | 0.14% |
| 12-Month Base Target | Rs 1,720 |
| Bull Case | Rs 2,060 |
| Downside Risk Level (not a target) | Rs 1,146 |
Why Is Vijaya Diagnostic Centre Share Price Target Set at Rs 1,720 for 2027?
The arithmetic is short. Trailing EPS of Rs 19.78 grown for one year gives a forward EPS estimate of Rs 23.74, and multiplying it by the unchanged PE of 72.44 gives the Rs 1,720 base-case Vijaya Diagnostic Centre stock target. The bull case adds faster earnings growth and a higher multiple, while the downside risk level assumes flat earnings and a lower multiple.
Earnings Growth Behind the Vijaya Diagnostic Centre Target Price: Five Years of Results
Vijaya Diagnostic Centre grew revenue from Rs 475.20 crore in FY22 to Rs 835 crore in FY26, a compound annual growth rate of 15.1%. Net profit grew more slowly, from Rs 110.67 crore to Rs 172.98 crore (11.8% a year), which points to margin pressure alongside the sales growth.
| Financial Year | Revenue (Rs Cr) | Net Profit (Rs Cr) | EPS (Rs) | Dividend per Share (Rs) |
|---|---|---|---|---|
| FY22 | 475.20 | 110.67 | 10.69 | 1.00 |
| FY23 | 473.37 | 85.21 | 8.26 | 1.00 |
| FY24 | 568.62 | 119.64 | 11.59 | 1.00 |
| FY25 | 699.71 | 143.79 | 13.92 | 2.00 |
| FY26 | 835.00 | 172.98 | 16.79 | 2.00 |
FY26 revenue growth was 19.3%, faster than the four-year average of 15.1%, and net profit moved up 20.3%. EPS rose from Rs 11.59 in FY24 to Rs 16.79 in FY26. The FY27 outlook depends on whether that EPS estimate keeps compounding.
Margins and the Latest Quarter
Vijaya Diagnostic Centre converted 20.7% of FY26 revenue into net profit, against 20.5% in FY25, within a five-year range of 18.0% to 23.3%. EBITDA margin was 42.8% in FY26 versus 41.5% in FY25.
In the September 2026 quarter, revenue was Rs 260.34 crore, up 25.3% from the same quarter a year earlier, while net profit of Rs 59.47 crore was up 37.4%. EBITDA came in at Rs 117.70 crore, up 33.6% year on year. The next quarterly result is the first test of whether the earnings assumption holds.
Balance Sheet and Cash Flow
Debt to equity stands at 0.48, and shareholders’ equity grew from Rs 469.54 crore in FY22 to Rs 957.15 crore in FY26. Operating cash flow in FY26 was Rs 270.59 crore against capital expenditure of Rs 182.72 crore, leaving free cash flow of Rs 87.87 crore, or 0.6% of the current market capitalisation. In FY25 free cash flow was Rs 128.92 crore.
Valuation Check for the Vijaya Diagnostic Centre Stock Target: PE, Price to Book and ROE
At a PE of 72.44 against an industry PE of 63.24, Vijaya Diagnostic Centre trades at a premium to its industry. Price to book is 13.96 on a book value of Rs 102.66 per share, and return on equity is 19.26%. A PE of 72.44 equals an earnings yield of 1.4%, and the FY26 dividend of Rs 2.00 per share gives a yield of 0.14%.
Shareholding Pattern and Institutional Holding
Promoters held 52.46% of Vijaya Diagnostic Centre in September 2026, and promoter holding has stayed near 52.46% since September 2025. Foreign institutional investors (FII) held 10.66% and domestic institutions (DII) held 32.50%, which puts total institutional holding at 43.16%. FII holding fell from 18.27% in September 2025 to 10.66% in September 2026. Public shareholders own the remaining 4.38%. A meaningful institutional holding adds a layer of research coverage and trading depth.
Vijaya Diagnostic Centre Share Price Targets for the Short Term and 12 Months
Short Term Vijaya Diagnostic Centre Stock Target Levels: Technical Setup
At Rs 1,461.20 on 6 November 2026, Vijaya Diagnostic Centre trades above its 50-day simple moving average of Rs 1,460.77 and above its 200-day exponential moving average of Rs 1,298.42. The 14-day RSI reads 66.6, which is neutral territory, and the MACD line sits above its signal line. The nearest resistance level is Rs 1,593.60 (52-week high) and the nearest support is Rs 1,460.77 (50-day simple moving average). A sustained move above Rs 1,593.60 would improve the short-term setup, while a close below Rs 1,460.77 would shift attention to the next support.
12 Month Vijaya Diagnostic Centre Target Price for 2027
The 12-month target of Rs 1,720 means a move of 17.7% up from Rs 1,461.20 over the next 12 months. It would also push the stock above its 52-week high of Rs 1,593.60. Anyone checking the Vijaya Diagnostic Centre share price target against their own view should focus on two inputs: the EPS estimate and the PE multiple.
How EPS Growth and PE Multiple Change the Vijaya Diagnostic Centre Target Price
| EPS Growth | PE 57.95 | PE 72.44 | PE 83.31 |
|---|---|---|---|
| 0.0% (EPS Rs 19.78) | Rs 1,146 | Rs 1,433 | Rs 1,648 |
| 20.0% (EPS Rs 23.74) | Rs 1,376 | Rs 1,720 | Rs 1,978 |
| 25.0% (EPS Rs 24.73) | Rs 1,433 | Rs 1,791 | Rs 2,060 |
Each cell multiplies the forward EPS estimate by the PE shown. Reading across a row shows what a de-rating or re-rating does to the Vijaya Diagnostic Centre price forecast, and reading down a column shows what earnings growth is worth at a fixed multiple.
Bull Case and Downside Risk for Vijaya Diagnostic Centre Stock Target in 2027
Bull Case Rs 2,060
The bull case Vijaya Diagnostic Centre price target needs EPS growth of 25.0%, which lifts forward EPS to Rs 24.73, and a PE multiple that rises 15% to 83.31. That gives Rs 2,060, 41.0% above the current price and above the 52-week high of Rs 1,593.60, so the stock would have to set a fresh 52-week high.
Downside Risk Level Rs 1,146
The downside risk level is not a target. It assumes EPS stays flat at Rs 19.78 and the PE falls 20% to 57.95. That gives Rs 1,146, 21.6% below the current price and above the 52-week low of Rs 848.00.
| Scenario | EPS Growth | PE Multiple | Price (Rs) | Change vs CMP |
|---|---|---|---|---|
| Bull Case | 25.0% | 83.31 | Rs 2,060 | +41.0% |
| Base Case | 20.0% | 72.44 | Rs 1,720 | +17.7% |
| Downside Risk | 0.0% | 57.95 | Rs 1,146 | -21.6% |
Key Risks to the Vijaya Diagnostic Centre Target Price for 2027
Growth Slowdown Risk for the Vijaya Diagnostic Centre Price Target
Revenue in the September 2026 quarter was up 25.3% year on year, and FY26 revenue growth was 19.3%. If growth slows from here, the EPS estimate behind the Vijaya Diagnostic Centre stock target will need revising.
Liquidity and Size Risk
Vijaya Diagnostic Centre has a market capitalisation of Rs 14,759 crore. Institutional holding is 43.16%, and promoters hold 52.46%. Stocks of this size are usually liquid, though exits can take longer than entries when the market is falling.
Valuation and Margin Risk
Net margin was 20.7% in FY26, and a squeeze from higher costs or weaker pricing would hit earnings first. At a PE of 72.44 versus an industry PE of 63.24, a de-rating toward the downside-risk PE of 57.95 would cut the price even if earnings hold.
Market and Technical Risk
Technical indicators add short-term risk: the 14-day RSI is 66.6 and the MACD sits above its signal line. A broad fall in the Nifty 50 or the Sensex can override company fundamentals for weeks at a time. That applies to any Vijaya Diagnostic Centre stock target, however carefully it is built.
How to Invest in Vijaya Diagnostic Centre
Start with the live price and volume. Any Vijaya Diagnostic Centre share price target is only as current as the data behind it, and the data here is as of 6 November 2026, so refresh the Rs 1,461.20 price before acting on any level.
Next, review the fundamentals yourself. The Univest Screener lets you check Vijaya Diagnostic Centre’s PE, ROE, debt and shareholding in one place.
Check Vijaya Diagnostic Centre fundamentals on the Univest Screener
Then compare the three Vijaya Diagnostic Centre target price scenarios with your own view. If you expect EPS growth below 20.0%, the base case is too optimistic for you; if you expect more, the bull case deserves weight.
Decide your position size and exit levels before you buy. The support and resistance levels above can serve as reference points, but they are not recommendations.
Finally, place the order through a SEBI-registered broker or the Univest app, and review the position after each quarterly result. Consult a SEBI-registered advisor if you are unsure.
Download the Univest iOS App or Univest Android App to track Vijaya Diagnostic Centre live price and get daily stock recommendations.
Conclusion
The Vijaya Diagnostic Centre share price target for 2027 is Rs 1,720 in the base case, with Rs 2,060 as the bull case. The support for that view is arithmetic you can check: EPS grew 20.4% a year over FY24 to FY26, and the stock trades at a PE of 72.44. The risks are equally concrete, including a PE of 72.44 that sits above the industry PE of 63.24 and a downside scenario that cuts the price 22% if earnings stall. Use these numbers as a framework, check them against the latest filings, and size any position to your own risk appetite.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Vijaya Diagnostic Centre Share Price Target 2027
What is the Vijaya Diagnostic Centre share price target for 2027?
Ans. The base-case Vijaya Diagnostic Centre share price target for 2027 is Rs 1,720, which is 17.7% above the price of Rs 1,461.20 on 6 November 2026. The bull case is Rs 2,060 and the downside risk level, which is not a target, is Rs 1,146. All three come from one method: forward EPS multiplied by a PE multiple, using only reported results. They are model estimates and not guaranteed outcomes, and the next quarterly result is the first check on the EPS assumption.
What is the Vijaya Diagnostic Centre share price today?
Ans. As of 6 November 2026, 9:57 AM IST, Vijaya Diagnostic Centre (NSE: VIJAYA) trades at Rs 1,461.20, up 1.63% on the day. That is 8.3% below the 52-week high of Rs 1,593.60 and 72.3% above the 52-week low of Rs 848.00. The market capitalisation of Rs 14,759 crore places it among mid-cap stocks. Prices change through the trading session, so check the live quote before acting on any level in this article.
Is Vijaya Diagnostic Centre a buy or sell at the current price?
Ans. The data points both ways. On the positive side, EPS has grown 20.4% a year over FY24 to FY26 and the base case implies 17.7% upside; on the cautious side, the PE of 72.44 is above the industry PE of 63.24, and the downside risk level of Rs 1,146 is 22% below the current price. Whether Vijaya Diagnostic Centre fits your portfolio depends on your time horizon, position size and risk appetite. Consult a SEBI-registered advisor before investing, as this article is not investment advice.
What are the bull case target and downside risk level for Vijaya Diagnostic Centre shares?
Ans. The bull case in the Vijaya Diagnostic Centre share price target for 2027 is Rs 2,060, which assumes 25.0% EPS growth and a PE of 83.31, a 15% re-rating from today’s multiple. That is 41.0% above the current price and above the 52-week high of Rs 1,593.60, so the stock would have to set a fresh 52-week high. The downside risk level is Rs 1,146, which assumes flat EPS and a PE of 57.95, 20% lower than today. It sits 21.6% below the current price and above the 52-week low of Rs 848.00, and it marks a risk to watch, not a target.
What are the main risks to the Vijaya Diagnostic Centre price target?
Ans. Four risks matter most for the Vijaya Diagnostic Centre share price target: slower revenue or profit growth, a PE de-rating, thin liquidity or size risk, and weakness in the broader market. With a market capitalisation of Rs 14,759 crore, the stock is usually liquid, though exits can take longer than entries in a falling market. A fall to the downside-risk PE of 57.95 would cut the price even if earnings hold.
What is the PE ratio of Vijaya Diagnostic Centre and how does it compare with the industry?
Ans. The PE ratio of Vijaya Diagnostic Centre is 72.44, against an industry PE of 63.24, which is a premium to the industry. Price to book is 13.96 and return on equity is 19.26%, and the PE equals an earnings yield of 1.4%. The base case holds the PE unchanged, so the Vijaya Diagnostic Centre share price target moves only with earnings, while the bull and downside scenarios change the multiple by +15% and -20%.
Who owns Vijaya Diagnostic Centre, and what is the promoter holding?
Ans. Promoters held 52.46% of Vijaya Diagnostic Centre in September 2026. FII held 10.66%, DII held 32.50% and the public held 4.38%. Together the two institutional groups hold 43.16%. Shareholding is filed every quarter, so it is worth rechecking after each result.
What were Vijaya Diagnostic Centre’s latest quarterly results?
Ans. In the September 2026 quarter, Vijaya Diagnostic Centre reported revenue of Rs 260.34 crore (up 25.3% year on year) and net profit of Rs 59.47 crore (up 37.4%). For comparison, FY26 full-year revenue growth was 19.3% and net profit moved up 20.3%. Each new quarter either supports or weakens the EPS growth of 20.0% assumed in the base case.